Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Arthritis, Rheumatoid 5Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell 3Leukemia, Myeloid, Acute 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Non-Hodgkin 2Leukemia 2Breast Neoplasms 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Unresectable Pancreatic Carcinoma 1Solid Tumors 1Small Cell Lung Carcinoma 1Sarcoma, Kaposi 1Pancreatic Adenocarcinoma 1Ovarian Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Multi-centric Castleman's Disease 1Melanoma 1Lymphoma 1Lymphohistiocytosis, Hemophagocytic 1Hodgkin Disease 1Hematologic Neoplasms 1Colitis 1Castleman Disease 1Carcinoma, Transitional Cell 1Carcinoma, Neuroendocrine 1

Interventions

Doxorubicin 15Zidovudine 12Vincristine 11Bleomycin 10Interferon alpha-2 6Cyclophosphamide 5tecogalan 4sargramostim 4Methotrexate 4Liposomes 4Leucovorin 4Filgrastim 4Etoposide 4Dexamethasone 4Cytarabine 4Fluorouracil 3interferon alfa-n1 2Valganciclovir 2Tumor Necrosis Factor-alpha 2Thalidomide 2Rituximab 2Ritonavir 2Nivolumab 2Mitoxantrone 2Isotretinoin 2Interleukin-2 2Electrocoagulation 2Didanosine 2Allopurinol 2ziconotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Acquired Immunodeficiency Syndrome × tocilizumab × Clear all
NCT01441063 2020-10-27

Tocilizumab for KSHV-Associated Multicentric Castleman Disease

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
8 enrolled 18 charts
LymphoidSarcoma

Multi-centric Castleman's Disease, Acquired Immunodeficiency Syndrome, Castleman Disease, Sarcoma, Kaposi

Data powered by HemOnc (CC BY 4.0) Colophon âš¡